RESUMEN
Background: Antibiotic resistance of Acinetobacter baumannii causes various communicable diseases and increases the risks of admission to intensive care units [ICUs] with high morbidity and mortality rates
Objectives: Evaluating the efficacy of colistin usage guidelines and recommendations among critically ill patient infected by a multidrug-resistant Acinetobacter baumannii
Methods: An observational cross sectional study that was performed during the period from June to August 2017 among 127 critically ill patients who were treated with colistin for multidrug-resistant Acinetobacter baumannii using bacterial culture and proper identification methods. Evaluations of CRP, bacterial culture, BUN and serum creatinine level were routinely done pre- and post-treatment
Results: The method of administrating colistin was through intravenous infusion among all the patients and the most common indication of colistin usage were pneumonia followed by UTI. All the patients were susceptible to colistin and shown a negative bacterial cultures among most of the patients. The creatinine level was elevated [>2 mg/dL] showing nephrotoxicity among 11% of the patient. No allergic, neurological effects or mortality rates were observed in the study
Conclusion: The findings of the recent study revealed that colistin is the best therapeutic treatment for A. baumannii in KSA hospitals due to their broad-spectrum activity that may make them the most important choice for serious communicable and hospital acquired infections. Proper monitoring of the side-effects of colistin especially nephrotoxic effects through routine evaluation of creatinine level to detect the renal injury and adjusting the doses or combination of colistin low dose with other antibiotics